Compare Deckers Outdoor Corp (DECK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Deckers Outdoor Corp trades at $82.98 (market cap $11.24B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.8× Deckers Outdoor Corp's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DECK | REGN | |
|---|---|---|
Market Cap | $11.24B | $76.14B |
Volume | 3,010,945 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $852.03 |
52-Week Low | $77.51 | $557.73 |
Typical Hold Time | 71 Days | 107 Days |
Enterprise Value | $10.11B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $80.38, down 1.57% on the day, with a neutral technical signal and strong fundamentals. Revenue grew to $4.99B in 2025, net income reached $966.09M, and profitability metrics like ROE of 42.56% are robust. Recent earnings beats and analyst upgrades reflect optimism, while cash flow trends show operational strength despite a projected net outflow in 2026.
The outlook is positive given valuation discounts (P/E 11.74), consistent earnings outperformance, and bullish analyst targets averaging $117.13. Risks include reliance on key brands HOKA and UGG, competitive pressures, and potential macroeconomic headwinds affecting consumer discretionary spending.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
